# A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

> **NCT02976129** · PHASE2 · COMPLETED · sponsor: **VHsquared Ltd.** · enrollment: 125 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** V565
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02976129
- **Lead sponsor:** VHsquared Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2019-03-08
- **Final completion:** 2019-03-08
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02976129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02976129, "A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02976129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*